5.11
-0.845(-14.20%)
Currency In USD
| Previous Close | 5.95 |
| Open | 5.35 |
| Day High | 5.5 |
| Day Low | 4.98 |
| 52-Week High | 13.68 |
| 52-Week Low | 4.25 |
| Volume | 7.79M |
| Average Volume | 783,468 |
| Market Cap | 280.26M |
| PE | -9.12 |
| EPS | -0.56 |
| Moving Average 50 Days | 5.79 |
| Moving Average 200 Days | 5.55 |
| Change | -0.85 |
If you invested $1000 in Candel Therapeutics, Inc. (CADL) since IPO date, it would be worth $729.29 as of February 21, 2026 at a share price of $5.105. Whereas If you bought $1000 worth of Candel Therapeutics, Inc. (CADL) shares 3 years ago, it would be worth $2,418.29 as of February 21, 2026 at a share price of $5.105.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Candel Therapeutics Announces Proposed $100 Million Public Offering
GlobeNewswire Inc.
Feb 19, 2026 9:05 PM GMT
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
GlobeNewswire Inc.
Feb 19, 2026 9:01 PM GMT
RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized prostate cancer Royalties based
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
GlobeNewswire Inc.
Feb 11, 2026 1:05 PM GMT
NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer